

## Strategic priorities for the OECI

### Quality improvement in Cancer Care and Research

The Accreditation and Designation Programme, specifically designed for cancer centres, aims to constantly improve our cancer centres' organisation. Although physicians, nurses and researchers constitute the core of cancer care and research, a seamless organisation, efficient logistics and state of the art, complex infrastructure are needed in order to deliver high quality care to a maximum of cancer patients, throughout Europe, and with a multidisciplinary approach. About 50% of the OECI Members are already included in the A&D Programme. The OECI quality approach is now recognised as the only existing European process specifically designed for cancer centres, providing a significant impact in the quality of cancer care in Europe. The certified Institutes represent the so-called "OECI Quality Network".

In addition to the A&D Programme, OECI established a detailed and focused benchmarking of comprehensive cancer care to transfer best practices amongst OECI members, as well as disseminating them across the entire cancer community.

### Enhancing the partnership patients-cancer institutes

Although in-depth integration of cancer research into care and education are the tripod of OECI objectives, the Organisation is moving towards enhancing the partnership with patient associations, involving cancer patients into our thinking and actions. This interest is confirmed by the strategic alliance with the European Cancer Patient Coalition - ECPC, with whom the OECI agreed on specific initiatives to empower the involvement of patients. Bringing together patient organisations and cancer institutes will provide a coherent picture of today's cancer patients' expectations, ranging from: quality of care to information on survivorship and medical nutrition, improvement in the quality of interdisciplinary patient treatment, harmonisation in oncology healthcare practices and patient advocacy capacity to effectively tackle cancer care inequalities in Europe. The foundation of this initiative is a jointly agreed Declaration between Patients and Health Care Providers.

### Biobanks and Molecular Pathobiology

Handling tumour heterogeneity and molecular signatures are the basis of the stratification of cancer patients, and clinical research is increasingly integrated with practical medical applications. In view of the crucial role of pathology departments, and of the expected "influx" of new markers and diagnostics in a scope of "OMICS", the OECI WG on Biobanks and Molecular Pathobiology acts in close cooperation with the European Association for Cancer Research EACR, the BBMRI European infrastructure, the European Society of Pathology and the IMPACTS network.

The aims of the WG is to avoid irreproducibility of clinical research, to accelerate the waiting time for biomarkers validation, to give to cancer centres of excellence more opportunities to define personalised treatments, and to improve the use of clinical tissues.

The OECI collaborates with the European biobanks Infrastructures (BBMRI-ERIC) for Archive tissues, with the European Society of Pathology (ESP) for the standardisation of analysis methods, with CEN to improve pre-analytical conditions of tissues, with EACR by organising courses and meetings.

### Cancer Outcomes Research

A new working group on cancer outcomes research has been activated in response to the need of following-up prospectively cohorts of patients. For CCCs located in areas covered by population registries, comparative analyses between population and clinical sets of patients will be possible, using EURO CARE and High Resolution data on survival and outcomes.

### OECI and rare cancers

OECI is particularly involved in the care of patients suffering from rare cancers. An even higher discrepancy in patient outcomes, depending where they are treated, is still observed. OECI coordinates the work package on quality of care of the Joint Action on Rare Cancers, recently launched by the Directorate General for Health and Consumer Protection of the European Commission. OECI also acts as associate partner and facilitator of the European Reference Network on rare solid tumours in adults; an impressive network of cancer centres of reference for rare cancers that is partially based on OECI quality standards. The network, coordinated by the Centre Léon Bérard in Lyon, involves several cancer centres from 18 countries, with a large percentage coming from OECI membership.

### Palliative care

The mandate of a comprehensive cancer centre is to prevent, cure and ensure the best quality of life for all patients, independently of their prognosis. The development of a modern, palliative care approach, which is not only concentrated on the last days/weeks of a patient's life. A specific Working Group on Palliative Care has been launched in order to discuss an agreed mission for the "Palliative Care Unit", with a specific focus on establishing common research and developing standards for palliative care provision.

### Education and Training

Educational activities focus, more particularly, on the above mentioned fields and are flourishing in order to strengthen the OECI objectives and to disseminate the acquired knowledge. A special educational programme is jointly developed with the European Association for Cancer Research "EACR". The OECI is also involved in broadcasting the educational programme of the European School of Oncology "ESO", a full OECI member. A specific e-learning programme is under development with the *ecancermedicalscience* journal.

### Communication and Dissemination

Regular updates of the Organisation are published on the website [oeeci@oeeci.eu](mailto:oeeci@oeeci.eu). *ecancermedicalscience* (the official OECI e-journal), hosts cutting edge papers, news, reports and videos. Formal collaborations have been established with the following reviews: *Cancerworld* [www.cancerworld.org](http://www.cancerworld.org), and *Tumori Journal* [www.tumorijournal.com](http://www.tumorijournal.com). Both the printed versions are distributed free of charge to the OECI Members and host announcements of OECI events and initiatives.

OECI  
BOARD  
2016



**President**  
Dominique de Valeriola  
Brussels, Belgium



**Former President**  
Wim H. van Harten  
Amsterdam, The Netherlands



**Elected Member**  
Carlos Caldas  
Cambridge, United Kingdom



**Elected Member**  
József Lövey  
Budapest, Hungary



**Elected Member**  
Thierry Philip  
Paris, France



**OECI Director**  
Claudio Lombardo  
Brussels, Belgium - Genoa, Italy



**Executive Secretary**  
Marco A. Pierotti  
Milan, Italy



**Treasurer**  
José Maria Laranja Pontes  
Porto, Portugal



**Elected Member**  
Christof von Kalle  
Heidelberg, Germany



**Elected Member**  
Gunnar Sæter  
Oslo, Norway



**OECI Central Office**  
Guy Storme  
Brussels, Belgium

WORKING  
GROUP AND  
ACTIVITIES



**Accreditation and Designation**  
Simon Oberst  
Cambridge, United Kingdom



**Biobanks and Molecular Pathobiology**  
Giorgio Stanta  
Trieste, Italy



**Cancer Economics and Benchmarking**  
Wim H. van Harten  
Amsterdam, The Netherlands



**Cancer Outcomes Research**  
Milena Sant  
Milan, Italy



**Supportive and Palliative Care**  
Pending



**Collaboration for Good Practices with Patients**  
Dominique de Valeriola  
Brussels, Belgium



**START-OECI**  
Lisa Licitra  
Milan, Italy



**Communication and Dissemination**  
Gordon McVie  
Milan, Italy



Claudio Lombardo  
Brussels, Belgium  
Genoa, Italy

OECI-EEIG Central Office  
c/o Fondation Universitaire  
11, Rue d'Egmont  
B-1000 Brussels, Belgium  
Phone: +32 2 512 0146

[www.oeeci.eu](http://www.oeeci.eu)  
[oeeci@oeeci.eu](mailto:oeeci@oeeci.eu)

December 2016



Organisation  
of European  
Cancer Institutes

*ecancermedicalscience*

Official OECI Journal

DEVELOPING  
THE FUTURE IN  
COMPREHENSIVE  
CANCER CARE


ONE MORE REASON  
TO JOIN THE OECI,  
IS CERTIFYING  
YOUR EXCELLENCE  
IN ONCOLOGY!



## OECI Objectives

The OECI is a network of cancer Institutions established to create a critical mass of expertise and competences and contributing to the production and dissemination of knowledge, so as to reduce fragmentation and increase competitiveness. These goals are being achieved by promoting and strengthening the concept of “comprehensiveness”, supporting quality in cancer care also through a well-structured internal organisation. OECI aims to accelerate the production and application of personalised care approaches, and to ensure equal rights to all cancer patients, with the ultimate goal of finding new and better treatments, providing more comprehensive care and improving patient quality of life, through evidence-based medicine. The increasing interest from international organisations, stakeholders & the cancer community in the OECI points to the growing importance of a comprehensive cancer network of institutions, where the entire chain of cancer care provision is present.

Dominique de Valeriola  
OECI President




“ The OECI is a non-governmental, non-profit Organisation founded in Vienna in 1979 and remodelled in 2005 into OECI-EEIG, a European Economic Interest Grouping, headquartered in Brussels. Today, the OECI counts 78 Member Institutes, which include some of the most prominent European Comprehensive Cancer Centres ”

## OECI NETWORK 2016

### The OECI membership 2016

#### Austria

- Comprehensive Cancer Center Graz, Graz
- Comprehensive Cancer Center Vienna, Wien
- Zentrum für Tumorerkrankungen Linz  
Onkologisches Leitspital für Oberösterreich, Linz

#### Belgium

- ★ Institut Jules Bordet (IJB), Brussels
- ★ Kankercentrum Brussel, Brussels
- ★ AZ Groeninge, Kortrijk
- Institut Roi Albert II, Brussels

#### Croatia

- Klinika za tumore Klinicki bolnicki centar  
Sestre milosrdnice, Zagreb

#### Czech Republic

- ★ Masarykův onkologický ústav, Brno
- Institut biostatistiky a analýz Lékařské a  
Přirodovědecké fakulty Masarykovy university,  
Brno

#### Denmark

- ★ Vejle Sygehus-Patienternes  
Kræftsygehus, Vejle
- Kræftens Bekæmpelse Center  
for Kræftforskning, Copenhagen

#### Estonia

- ★ Sihtasutus Tartu Ülikooli Kliinikum, Tartu
- North Estonia Medical Centre, Tallin

#### Finland

- ★ HYKS Syöpäkeskus Helsinki  
University, Helsinki
- TYKS Syöpäkeskus, Turku
- Tampere University Hospital, Tampere

#### France

- ★ Gustave Roussy, Villejuif
- ★ Centre Léon Bérard, Lyon
- ★ Institut Curie, Paris
- Centre de Lutte Contre le Cancer  
Paul Strauss, Strasbourg
- Centre Henri Becquerel, Rouen

#### Germany

- Deutsches Krebsforschungszentrum (DKFZ),  
Heidelberg
- Universitäts KrebsCentrum Dresden, Dresden
- Charité Comprehensive Cancer Centre, Berlin

#### Hungary

- ★ Országos Onkológiai Intézet, Budapest
- Országos Korányi TBC és Pulmonológiai  
Intézet, Budapest

#### Italy

- ★ Centro di Riferimento Oncologico,  
Istituto Nazionale Tumori, Aviano

- ★ IRCCS Azienda Ospedaliera  
Universitaria San Martino - IST -  
Istituto Nazionale per la Ricerca sul  
Cancro, Genova

- ★ Istituto Europeo di Oncologia, Milano

- ★ Fondazione IRCCS Istituto Nazionale  
dei Tumori di Milano, Milano

- ★ Istituto Nazionale Tumori Regina Elena,  
Roma

- ★ Istituto Oncologico Veneto IRCCS-IOV,  
Padova

- ★ Istituto Tumori Giovanni Paolo II,  
Istituto di Ricovero e Cura a Carattere  
Scientifico, Bari

- ★ Istituto Nazionale Tumori IRCCS  
“Fondazione G.Pascale” (INT-Pascale),  
Napoli

- ★ IRCCS, Centro di Riferimento Oncologico  
della Basilicata (CROB), Rionero in Vulture

- ★ Azienda Ospedaliera Arcispedale  
S. Maria Nuova IRCCS Istituto in  
Tecnologie Avanzate e Modelli Assistenziali  
in Oncologia, Reggio Emilia

- ★ IRCCS Istituto Clinico Humanitas, Milano
- Ospedale S. Raffaele (OSR), Milano

- European School of Oncology (ESO), Milano
- IFOM - FIRCC Institute of Molecular Oncology,  
Milano

- Istituto Scientifico Romagnolo per lo Studio  
e la Cura dei Tumori [IRST]-IRCCS, Meldola - Forlì
- IRCCS - Istituto di Ricerche Farmacologiche  
Mario Negri, Milano

- Ente Ospedaliero Ospedali Galliera, Genova
- Nerviano Medical Sciences Group S.r.l., Nerviano
- IRCCS Istituto Dermovenereologico S. Maria  
e S. Gallicano, Roma

#### Lithuania

- ★ National Cancer Institute, Vilnius

#### Norway

- ★ Oslo Universitetssykehus (OUS), Oslo

#### Poland

- Wielkopolskie Centrum Onkologii, Poznan

#### Portugal

- ★ Instituto Português de Oncologia do  
Porto Francisco Gentil E.P.E.  
(IPO-Porto), Porto

- ★ Instituto Português de Oncologia de  
Lisboa Francisco Gentil, E.P.E.  
(IPO-Lisboa), Lisbon

- ★ Instituto Português de Oncologia de  
Coimbra Francisco Gentil, E.P.E.  
(IPO-Coimbra), Coimbra

#### Romania

- ★ The “Prof. Dr. Ion Chiricută” Institute  
of Oncology (IOCN), Cluj
- SC RTC Radiology Therapeutic Center –  
Amethyst Radiotherapy, Otopeni

#### Russia

- Tatarstan Cancer Center “TCC”, Kazan
- N.N. Blokhin Russian Cancer Research  
Centre, Moscow
- P.A. Herzen Moscow Cancer Research  
Institute, Moscow

#### Serbia

- Oncology Institute of Vojvodina, Sremska Kamenica

#### Slovakia

- Ústav experimentálnej onkológie SAV, Bratislava

#### Slovenia

- Onkološki inštitut Ljubljana, Ljubljana

#### Spain

- ★ Fundación Instituto Valenciano de  
Oncología IVO, Valencia
- Institut Català d'Oncologia, L'Hospitalet  
de Llobregat - Barcelona
- Instituto Madrileño de Oncología (Grupo IMO),  
Madrid

#### Sweden

- Karolinska Institute and University Hospital,  
Stockholm
- Skåne University Hospital South  
Western Cancer Centre, Malmö

### The OECI Quality Network

- ★ OECI Members A&D certified
- ★ OECI Members in the A&D process
- Other OECI Members

